Q2 2026 BioLine RX Ltd Earnings Call Transcript
Key Points
- GLIX1 shows promising preclinical efficacy in GBM, including temozolomide-resistant models, and has a clean safety profile with excellent blood-brain barrier penetration.
- Phase 1/2a trial of GLIX1 is progressing well, with dosing in the second cohort underway and the third expected in September, ahead of schedule.
- Strong synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer models, supporting expansion into additional cancer types.
- Enrollment in the Phase 2b pancreatic cancer trial (chemo for MedPac) is tracking well, with an interim futility analysis expected later this year.
- Company has sufficient cash runway into the first half of 2027, supplemented by a recent $3.75 million offering and non-dilutive royalty revenue from APHEXDA sales.
- Net loss increased to $4.3 million in Q2 2026 from $3.9 million in Q2 2025, driven by higher R&D expenses for GLIX1.
- Cash position remains tight at $13.1 million, requiring additional financing to extend runway beyond early 2027.
- APHEXDA sales remain modest at $1.6 million in Q2 2026, with royalty revenue flat year-over-year, indicating slow market adoption.
- The pancreatic cancer program faces potential competitive pressure from new treatments like Revolution Medicines' thyroxin, which could impact motixafortide's future role.
- GLIX1 is still in early-stage development, with Phase 1 data not expected until the first half of 2027, leaving significant clinical and regulatory risks.
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx second quarter 2026 financial results conference call. (Operator Instructions)
I would now like to turn the call over to Chuck Padala, Investor Relations. Please go ahead.
Thank you, operator, and welcome, everyone, and thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release a copy of which is available in the Investor Relations section of our website was also filed as a 6-K. I'd like to remind everyone that certain statements we make during the call will be forward-looking, because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements.
For a full discussion of these risks and uncertainties please review our annual report on Form 20-F and our quarterly reports on Form 6-K that are filed with the US Securities and Exchange Commission. At this time,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
